

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumension Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT
OT-401 APPROVED FOR REAL WORLD STUDY IN HAINAN BOAO

This announcement is made by Ocumension Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Group’s core product, OT-401 (YUTIQ), has been approved to carry out the real world study in Boao Lecheng International Medical Tourism Pilot Zone (博鰲樂城醫療旅遊先行區) in Hainan Province, China, which is a significant milestone for the Company further highlighting its innovative strength and may potentially accelerate the new drug application submission of OT-401 in China.

OT-401 (YUTIQ), the core product of the Company is a first-in-class, innovative injectable, sustained-release micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye in-licensed from EyePoint Pharmaceuticals, Inc. OT-401 is a sterile non-bioerodible intravitreal implant designed to provide sustained release of a total of 0.18 mg of the active ingredient fluocinolone acetonide, a corticosteroid, at a controlled rate for up to 36 months from a single administration performed in an outpatient visit. To date, YUTIQ is the first and only uveitis treatment designed to deliver fluocinolone for up to 36 months that has been approved by the U.S. Food and Drug Administration.

The Company’s OT-401 real-world research data are expected to facilitate the commercialization process of OT-401 in China, benefiting from the Company’s scientific and rigorous real world study program and the detailed research and development strategy implemented by the Company’s professional ophthalmology clinical research team.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately commercialize OT-401 (YUTIQ) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Executive Director

Hong Kong, December 28, 2020

As of the date of this announcement, the Board comprises Dr. Lian Yong CHEN, Mr. Ye LIU, Dr. Zhaopeng HU and Dr. Wei LI as executive directors, Mr. Yanling CAO and Mr. Lefei SUN as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE, and Mr. Yiran HUANG as independent non-executive directors.